Section Arrow
NRIX.NASDAQ
- Nurix Therapeutics
Quotes are at least 15-min delayed:2026/05/11 02:58 EDT
Regular Hours
Last
 16.52
+0.24 (+1.47%)
Day High 
16.62 
Prev. Close
16.28 
1-M High
17.68 
Volume 
1.29M 
Bid
16.05
Ask
19
Day Low
16.225 
Open
16.29 
1-M Low
15.47 
Market Cap 
1.68B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.71 
20-SMA 16.66 
50-SMA 15.93 
52-W High 22.4999 
52-W Low 8.195 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.17/-2.89
Enterprise Value
1.74B
Balance Sheet
Book Value Per Share
4.65
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
83.98M
Operating Revenue Per Share
0.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TRAWTraws Pharma Inc2.18+0.48+28.24%2.07PE
VRAXVirax Biolabs Group Limited0.171+0.036+26.67%-- 
ASBPAspire Biopharma Holdings Inc.0.185+0.03+19.35%-- 
INOInovio Pharmaceuticals1.46+0.09+6.57%-- 
MRNAModerna54.35+5.81+11.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.